Phase Ib Study of the Immunocytokine Simlukafusp Alfa (FAP-IL2v) in Combination with Cetuximab in Patients with Head and Neck Squamous Cell Carcinoma
Aaron R. Hansen, Carlos A. Gomez-Roca, Debbie G. J. Robbrecht, Loic Verlingue, Antoine Italiano, Julie E. Bauman, Neeltje Steeghs, Hans Prenen, Jérôme Fayette, James Spicer, Jiaxin Niu, Christin Habigt, Meike Schneider, Stefan Evers, Nassim Sleiman, David Dejardin, Caroline Ardeshir, Daniela Schmid, · 2024
Read Phase Ib Study of the Immunocytokine Simlukafusp Alfa (FAP-IL2v) in Combination with Cetuximab in Patients with Head and Neck Squamous Cell Carcinoma by Aaron R. Hansen, Carlos A. Gomez-Roca, Debbie G. J. Robbrecht, Loic Verlingue, Antoine Italiano, Julie E. Bauman, Neeltje Steeghs, Hans Prenen, Jérôme Fayette, James Spicer, Jiaxin Niu, Christin Habigt, Meike Schneider, Stefan Evers, Nassim Sleiman, David Dejardin, Caroline Ardeshir, Daniela Schmid, (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11647204.txt.
Description
Aaron Hansen and co-authors report an early cancer drug trial in this 2024 paper. The trial tested an engineered immune drug, called FAP-IL2v, with cetuximab in head and neck cancer. Patients had cancer that had returned, could not be removed, or had spread.
The new drug targets a protein on tumor support cells and carries a tuned immune signal. It was designed to cut the toxic effects tied to older versions of that signal. Patients received the drug on a set schedule during the trial. Early trials like this one check safety and dose above all. The results guide larger tests of the pairing. Side effects and patient response were tracked with care throughout.
Catalog record
| CREATOR | Aaron R. Hansen, Carlos A. Gomez-Roca, Debbie G. J. Robbrecht, Loic Verlingue, Antoine Italiano, Julie E. Bauman, Neeltje Steeghs, Hans Prenen, Jérôme Fayette, James Spicer, Jiaxin Niu, Christin Habigt, Meike Schneider, Stefan Evers, Nassim Sleiman, David Dejardin, Caroline Ardeshir, Daniela Schmid, |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 28 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |